Immunicum AB (SE:IMMU)

:IMMU

IMMU

Immunicum AB

RESEARCH TOOLSreports

Immunicum AB (IMMU) Price & Analysis

3 Followers

IMMU Stock Chart & Stats

kr5.77

kr0.08(1.09%)

At close: Mar 06 4:00 PM EST

kr5.77

kr0.08(1.09%)

Day’s Range― - ―

52-Week Rangekr3.86 - kr10.98

Previous CloseN/A

Volume3.78K

Average Volume (3M)38.75K

Market Cap

kr271.88M

Enterprise Valuekr193.98M

Total Cash (Recent Filing)kr64.66M

Total Debt (Recent Filing)kr33.28M

Price to Earnings (P/E)―

Beta0.36

Next Earnings

May 08, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.74

Shares Outstanding62,584,580

10 Day Avg. Volume52,324

30 Day Avg. Volume38,751

Financial Highlights & Ratios

PEG Ratio0.14

Price to Book (P/B)0.50

Price to Sales (P/S)0.00

P/FCF Ratio-3.57

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-1.69

Revenue Forecast (FY)kr5.00M

Bulls Say, Bears Say

Bulls Say

Balance Sheet StrengthLow reported leverage and a meaningful equity base provide durable financial flexibility for a pre-revenue biotech. That stronger balance sheet relative to peers supports continued R&D spending, partnership negotiations, or bridge financing without immediate solvency risk.

Improving Cash BurnReduced negative free cash flow in 2024–2025 versus 2023 indicates progress toward lowering funding needs. A sustained decline in burn rate extends runway, reduces frequency of dilutive raises, and gives management more time to advance programs to value‑creating milestones.

Lean HeadcountA small, lean workforce limits fixed operating costs and preserves capital in a development‑stage biotech. This structural cost discipline helps extend runway, focusing limited resources on core programs and making spending adjustments easier across development cycles.

Bears Say

Persistent Losses & Zero RevenueZero recent revenue combined with ongoing operating losses means the company lacks commercial cash inflows to fund operations. Over the medium term this forces reliance on external funding and indicates the business has not achieved durable commercial traction.

Negative Cash GenerationConsistent negative operating and free cash flow creates structural dependence on financing. Repeated capital raises can dilute shareholders, limit strategic choices, and impose timing risk on R&D programs if markets tighten or partnership funding is not secured.

Eroding Equity BaseA declining equity and asset base erodes the company’s financial cushion and borrowing capacity over time. That trend increases vulnerability to adverse outcomes, raises refinancing risk, and could compress strategic flexibility if losses persist.

IMMU FAQ

What was Immunicum AB’s price range in the past 12 months?

Immunicum AB lowest stock price was kr3.86 and its highest was kr10.98 in the past 12 months.

What is Immunicum AB’s market cap?

Immunicum AB’s market cap is kr271.88M.

When is Immunicum AB’s upcoming earnings report date?

Immunicum AB’s upcoming earnings report date is May 08, 2026 which is in 32 days.

How were Immunicum AB’s earnings last quarter?

Immunicum AB released its earnings results on Feb 11, 2026. The company reported -kr0.74 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.74.

Is Immunicum AB overvalued?

According to Wall Street analysts Immunicum AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Immunicum AB pay dividends?

Immunicum AB does not currently pay dividends.

What is Immunicum AB’s EPS estimate?

Immunicum AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Immunicum AB have?

Immunicum AB has 62,584,580 shares outstanding.

What happened to Immunicum AB’s price movement after its last earnings report?

Immunicum AB reported an EPS of -kr0.74 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.055%.

Which hedge fund is a major shareholder of Immunicum AB?

Currently, no hedge funds are holding shares in SE:IMMU

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Immunicum AB

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is ilixadencel, which is in Phase II MERECA clinical trial for the treatment of kidney cancer; and Phase I/II clinical trial to treat liver cancer and gastrointestinal stromal tumors. The company's products also comprise DCP-001, which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia; and Phase I/II ALISON clinical trial for the treatment of ovarian cancers. It has a research collaboration with PCI Biotech Holding ASA for novel cancer vaccination treatment; and with Icahn School of Medicine at Mount Sinai. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.